Adverse events associated with nilotinib in chronic myeloid leukaemia: mechanisms and management strategies

Expert Rev Clin Pharmacol. 2021 Feb 23. doi: 10.1080/17512433.2021.1894129. Online ahead of print.ABSTRACTINTRODUCTION: Nilotinib is a second-generation tyrosine kinase inhibitor (TKI) targeting BCR/ABL, which is used for the first-line treatment of newly-diagnosed chronic myeloid leukemia (CML) patients and the second-line treatment of most CML patients who are resistant or intolerant to prior therapy that includes imatinib. In addition to common adverse reactions, long-term use of nilotinib shows some toxicities that are different from those of occurring during other BCR/ABL TKI treatment, such as cardiovascular toxicity. It is life-threatening, which would affect not only the choice of initial treatment of CML patients but also safety of long-term medication.AREAS COVERED: Through searching literature and reports from PubMed and clinical trials, here we review a profile of the adverse effects induced by nilotinib. We also discuss the potential molecular toxicological mechanisms and clinical management, which may provide strategies to prevent or intervene the toxicity associated with nilotinib.EXPERT OPINION: Severe adverse effects associated with nilotinib limit its long-term clinical application. However, the exact mechanisms underlying these toxicities remain unclear. Future research should focus on the developing strategies to reduce the toxicities of nilotinib as well as to avoid similar toxicity in the development of new drugs.PMID:33618586 | DOI:10.1080/17512433.2021...
Source: Expert Review of Clinical Pharmacology - Category: Drugs & Pharmacology Authors: Source Type: research